(Q43054066)

13 November 2017

title

Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein (English)

1 reference

13 November 2017

Wolfgang Glaesner

1

1 reference

13 November 2017

Andrew Mark Vick

2

1 reference

13 November 2017

Rohn Millican

3

1 reference

13 November 2017

Bernice Ellis

4

1 reference

13 November 2017

Sheng-Hung Tschang

5

1 reference

13 November 2017

Yu Tian

6

1 reference

13 November 2017

Krister Bokvist

7

1 reference

13 November 2017

Martin Brenner

8

1 reference

13 November 2017

Anja Koester

9

1 reference

13 November 2017

Niels Porksen

10

1 reference

13 November 2017

Garret Etgen

11

1 reference

13 November 2017

Tom Bumol

12

1 reference

13 November 2017

publication date

1 May 2010

1 reference

Diabetes - Metabolism: Research and Reviews

13 November 2017

published in

1 reference

13 November 2017

volume

26

1 reference

13 November 2017

issue

4

1 reference

13 November 2017

page(s)

287-296

1 reference

It's time to overcome clinical inertia

13 November 2017

cites work

1 reference

The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus

21 January 2018

1 reference

7 January 2021

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

7 January 2021

The barrier of hypoglycemia in diabetes

1 reference

7 January 2021

How our current medical care system fails people with diabetes: lack of timely, appropriate clinical decisions

1 reference

7 January 2021

Glycemic control and hypoglycemia: is the loser the winner?

1 reference

7 January 2021

An intervention to overcome clinical inertia and improve diabetes mellitus control in a primary care setting: Improving Primary Care of African Americans with Diabetes (IPCAAD) 8.

1 reference

7 January 2021

Biology of incretins: GLP-1 and GIP

1 reference

7 January 2021

The incretin system and its role in type 2 diabetes mellitus

1 reference

7 January 2021

Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV

1 reference

7 January 2021

Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum

1 reference

7 January 2021

Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes

1 reference

7 January 2021

Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics)--preclinical and clinical results

1 reference

7 January 2021

Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo

1 reference

7 January 2021

A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis.

1 reference

7 January 2021

Protein engineering strategies for sustained glucagon-like peptide-1 receptor-dependent control of glucose homeostasis

1 reference

7 January 2021

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study

1 reference

7 January 2021

Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled tr

1 reference

7 January 2021

The binding affinity of human IgG for its high affinity Fc receptor is determined by multiple amino acids in the CH2 domain and is modulated by the hinge region

1 reference

7 January 2021

In vitro characterization of five humanized OKT3 effector function variant antibodies.

1 reference

7 January 2021

Structural motifs involved in human IgG antibody effector functions

1 reference

7 January 2021

A therapeutic human IgG4 monoclonal antibody that depletes target cells in humans

1 reference

7 January 2021

Identifiers

DOI

10.1002/DMRR.1080

1 reference

13 November 2017

1 reference